Alector’s GSK-partnered dementia drug latozinemab fails in late-stage trial

Alector; GSK; latozinemab; dementia; frontotemporal dementia; Phase 3 trial; clinical trial failure; progranulin; drug development

Roche Claims Its SERD Is Most Potent After Positive Breast Cancer Data Presented at ESMO 2025

Roche; SERD; giredestrant; breast cancer; ESMO 2025; progression-free survival; oral SERD; ER-positive; HER2-negative; phase 3 trial

AstraZeneca and Daiichi Sankyo Report Landmark Results for Datroway in Triple-Negative Breast Cancer

Datroway; Datopotamab deruxtecan; triple-negative breast cancer; ADC; AstraZeneca; Daiichi Sankyo; clinical trial; overall survival; chemotherapy; TROP2; phase 3 trial; immunotherapy; TROPION-Breast02

Merck Makes Strong Case for Winrevair in Earlier-Stage Pulmonary Arterial Hypertension (PAH) Patients After Positive Phase 3 HYPERION Results

Winrevair; Merck; HYPERION study; PAH; sotatercept; clinical worsening; early disease; activin signaling; FDA approval; Phase 3 trial

BioNTech and DualityBio Achieve Phase 3 Success with ADC Therapy for HER2-Positive Breast Cancer, Advancing Oncology Pipeline

BioNTech; DualityBio; antibody-drug conjugate (ADC); HER2-positive breast cancer; trastuzumab pamirtecan; BNT323/DB-1303; phase 3 trial; progression-free survival; oncology pipeline; ADC market

Akeso, Summit’s PD-1xVEGF Drug Ivonescimab Shows Strong Progression-Free Survival Benefit in Global Lung Cancer Trial

Akeso; Summit Therapeutics; ivonescimab; PD-1xVEGF; bispecific antibody; non-small cell lung cancer; progression-free survival; Phase 3 trial; overall survival; FDA approval

Roche and AbbVie Announce Phase 3 Venclexta Trial Fails to Meet Primary Endpoint in High-Risk MDS

Roche; AbbVie; Venclexta; venetoclax; azacitidine; myelodysplastic syndromes; MDS; Phase 3 trial; VERONA study; clinical trial results; cancer drug